NNC0268-0965
- Generic Name
- NNC0268-0965
A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (insulin glargine)Drug: Placebo (NNC0268-0965)
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT04575181
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil GmbH & Co. KG, Mainz, Germany
A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT04136067
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Healthy VolunteersDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT03965013
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath